Welcome to 2019! This is the year for the estimated primary completion date of the clinical trials FortiColos and PreColos-RCT. The two studies aim to prove the benefits of application of bovine as first enteral nutrition for preterm infants.
What to expect in 2019?
One of the upmost anticipated events in 2019 are the completion of the clinical trials FortiColos and PreColos-RCT in Denmark and China. The two studies are expected to provide the first firm results of the benefits from using bovine colostrum as first enteral nutrition for preterm infants.
In PreColos-RCT bovine colostrum is used as dietary food supplement for the preterm infants when mother´s own milk is not available. The primary outcome measure is time to full enteral feeding, while the secondary outcome measures include combined incidence of severe neonatal infections (NEC, LOS, meningitis) and mortality, the presence of feeding intolerance, days on parental nutrition, days to regain birth weight and routine blood tests. Read more about PreColos-RCT here.
FortiColos focus on bovine colostrum as fortifier to the human donor milk provided to preterm infants when mother´s own milk is not available. Here, the primary outcome measure is body weight gain, incidence of necrotizing enterocolitis and incidence of late-onset sepsis. Secondary outcome measures include feeding intolerance, time to reach full enteral feeding, days on parental nutrition and blood values. Read more about FortiColos here.
Until the long awaited results from PreColos-RCT and FortiColos are published, we will take you through some of the published findings from 2018. Look forward to learn more about diet effect on DNA methylation, epigenetics of preterm neonates and the relation between bovine colostrum, systemic infections and bacterial crossing of the blood-brain barrier.